TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In interim results from the phase III ADAPT OCULUS trial, subcutaneous efgartigimod PH20 improved patient-reported ocular symptoms at four weeks compared with placebo. A combined patient-and-physician score also favored treatment, while the MG-ADL ocular measure did not show a statistically significant difference; the drug is not FDA-approved for ocular myasthenia gravis.
Subcutaneous efgartigimod PH20 improved the primary patient-reported ocular symptom score in a phase III trial of people with ocular myasthenia gravis, according to interim results presented by Vern Juel, MD, of Duke University School of Medicine. At week four, the score improved more with treatment than with placebo, though another key measure of daily activities did not show a statistically significant between-group difference.
In the ADAPT OCULUS trial, 141 participants with ocular myasthenia gravis were assigned to treatment or placebo. During the trial’s first part, participants received four weekly injections of 1,000 mg efgartigimod PH20 or placebo, followed by four weeks of follow-up. The primary endpoint was change from baseline to week four on the ocular section of the Myasthenia Impairment Index Patient Reported Outcome (MGII PRO).
The treatment group had a mean 4.04-point improvement in that score, compared with a 1.99-point improvement in the placebo group. The mean difference was 2.05 points (P=0.012), Juel reported at the American Association of Neuromuscular and Electrodiagnostic Medicine meeting. On a second measure combining patient reports with physician examination, the mean improvement was 5.02 points with efgartigimod and 2.57 with placebo, a 2.44-point difference (P=0.018).
The MG-ADL ocular domain, another key secondary outcome, showed a similar numerical direction but no statistically significant difference between groups (P=0.60). Juel said efgartigimod improved diplopia, or double vision, and ptosis, or drooping eyelids. Those symptom findings were reported by the investigator; the supplied results do not provide separate effect sizes for either symptom.
Measuring Ocular Symptom Change
The results address a treatment gap in ocular myasthenia gravis, which affects eye muscles and can cause double vision and eyelid drooping. Juel said the condition has historically been understudied and that there is an unmet need for safe, effective, targeted therapies. A positive primary endpoint in a dedicated phase III study gives clinicians and researchers trial evidence focused on this patient group rather than relying only on findings from generalized myasthenia gravis.
The mixed outcome measures matter when interpreting the findings. The MGII PRO ocular score and the combined patient-and-physician score favored treatment with statistically significant differences, but the MG-ADL ocular score did not. The results support further attention to how trials capture patients’ symptoms and daily impact; they do not establish that every measure of ocular function improved or that patients will experience the same benefit.
For patients, the findings are not yet an approval or a change in prescribing status: efgartigimod is not FDA-approved for ocular myasthenia gravis. Any treatment decision remains a matter for a qualified clinician familiar with an individual’s condition and available options.
Products Worth Considering
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
From Generalized to Ocular MG
Efgartigimod is an antibody fragment that binds to the neonatal Fc receptor, reducing circulating immunoglobulin G autoantibodies. The source report says the intravenous formulation was approved in 2021 for generalized myasthenia gravis in people with anti-acetylcholine receptor antibodies, and a subcutaneous formulation with hyaluronidase was approved in 2023. Those approvals concern generalized disease, not the ocular indication studied in ADAPT OCULUS.
The trial enrolled people with MGFA class I disease, an MGII PRO ocular score of at least 6, and any antibody serotype. Participants were taking stable doses of existing therapies, including acetylcholinesterase inhibitors, corticosteroids, or other immunosuppressive medicines. Of the 71 people assigned to efgartigimod, 81.3% had anti-AChR antibodies and 16.9% were triple seronegative, according to the report.
Part B of the study was an open-label extension in which participants received multiple treatment cycles. Juel reported score improvements across cycles in both anti-AChR and triple-seronegative groups. Because the extension was open-label, those observations are distinct from the placebo-controlled comparison in part A.
“Efgartigimod significantly improved diplopia and ptosis in patients with ocular myasthenia gravis.”
— Vern Juel, MD, Duke University School of Medicine
Approval and Longer-Term Benefit
The supplied report gives interim trial results, not a final regulatory decision. It does not state when the full results will be published, whether further analyses may change the interpretation, or whether regulators will consider an application for an ocular myasthenia gravis indication. The medication is not currently FDA-approved for that condition.
The report also does not provide detailed estimates of how long score improvements lasted for each participant or how large a change patients would consider meaningful in everyday life. Although part B followed multiple treatment cycles, it was open-label, and the information provided does not establish long-term comparative benefit against placebo.
Further Trial and Regulatory Updates
Further reporting will depend on additional ADAPT OCULUS data, including fuller analyses of efficacy and safety and any updates from the study investigators or argenx. The trial included an open-label extension, but the source material does not give a date for its completion or for publication of final results.
Regulatory steps are also unknown. No FDA application or review timeline for ocular myasthenia gravis is specified in the report. Until the indication is approved, the trial findings remain evidence from a clinical study rather than a new FDA-authorized use.
Key Questions
What did the ADAPT OCULUS trial find?
At four weeks, participants receiving subcutaneous efgartigimod PH20 had a greater mean improvement in the MGII PRO ocular score than those receiving placebo: 4.04 points versus 1.99. The between-group difference was 2.05 points (P=0.012).
Did every key outcome reach statistical significance?
No. The combined MGII PRO plus physician examination score favored treatment with a statistically significant difference. The MG-ADL ocular domain also moved in a similar numerical direction, but its between-group difference was not statistically significant (P=0.60).
Is efgartigimod approved for ocular myasthenia gravis?
No. The source report says efgartigimod is not currently FDA-approved for ocular myasthenia gravis. Existing approvals described in the report are for other conditions or forms of myasthenia gravis.
Who took part in the trial?
The study enrolled 141 people with MGFA class I ocular myasthenia gravis, any serotype, and an MGII PRO ocular score of at least 6. Participants were on stable doses of specified background treatments when they entered the study.
What safety information was reported?
Juel said adverse events were consistent with prior clinical studies and real-world evidence in generalized myasthenia gravis. Headache, injection-site redness, and upper respiratory tract infections were the most common treatment-emergent events; the report counted one serious event in part A and 17 events across parts A and B combined.
Source: rss
